Futibatinib for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing futibatinib, an oral medication, in patients with specific genetic changes in their cancer. It aims to block proteins that help cancer grow, targeting those who may not respond well to typical treatments. Futibatinib has shown selective antitumor activity in various tumors.
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors, gastric or gastro-esophageal junction cancer, and certain blood cancers that have specific FGFR genetic changes. Participants must have measurable disease and should have tried standard treatments without success. They can't join if they've had prior FGFR inhibitor treatment or significant eye, mineral balance disorders, or unstable brain metastases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive futibatinib at an oral dose of 20 mg once a day on a continuous 28-day cycle until disease progression or unacceptable toxicity
Follow-up
Participants are monitored for survival every 12 weeks until survival events have been reported for 75% of enrolled patients or the study is terminated
What Are the Treatments Tested in This Trial?
Interventions
- Futibatinib
Futibatinib is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Taiho Oncology, Inc.
Lead Sponsor
Tim Whitten
Taiho Oncology, Inc.
Chief Executive Officer since 2018
MBA and Pharmacy degree
Harold Keer
Taiho Oncology, Inc.
Chief Medical Officer
MD, PhD